Toward gene therapy for human CD3 deficiencies

A Pacheco-Castro1, J M Martín-Fernández, R Millán

  • 1Inmunología, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.

Human Gene Therapy
|November 25, 2003
PubMed

Insights

Gene therapy using CD3gamma corrected T cell receptor defects in patients with CD3 deficiencies. However, this approach may cause harmful autoreactivity by disrupting T cell calibration.

Area of Science:

  • Immunology
  • Molecular Biology
  • Gene Therapy

Background:

  • The T cell receptor-CD3 complex (TCR-CD3) is crucial for T lymphocyte function, regulating surface expression and signal transduction.
  • Deficiencies in CD3 chains lead to severe immune impairments, potentially causing lethal outcomes.

Purpose of the Study:

  • To investigate the feasibility of gene therapy for treating human CD3 deficiencies.
  • To assess the efficacy and potential adverse effects of delivering a functional CD3 chain.

Main Methods:

  • Retroviral transduction of CD3gamma into peripheral blood T lymphocytes from CD3gamma-deficient patients.
  • Analysis of TCR-CD3 expression and activation-induced downregulation post-transduction.

Main Results:

  • Gene transfer selectively corrected TCR-CD3 expression and downregulation defects.
  • Unexpected adverse effects were observed, suggesting an autoreactive recognition mechanism.

Conclusions:

  • Gene therapy is a feasible approach for human CD3 deficiencies.
  • Gene transfer into postthymic lymphocytes may disrupt intrathymic calibration, leading to harmful autoreactivity.

Related Concept Videos